Menu
Recruiting NCT07110376

Deep Brain Stimulation Neural Recordings of Varied Stimulation During Sleep in Parkinson's Disease

No phase Interventional Parkinson Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Nighttime Deep Brain Stimulation with Varying Amplitude Settings.
Who it may be relevant to
Registry conditions: Parkinson Disease. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Deep Brain Stimulation Neural Recordings of Varied Stimulation During Sleep in Parkinson's Disease - The DREAMS-PD Study

Overview

This study employs an exploratory, prospective, single center, naturalistic clinical trial design with a randomized crossover intervention.

Detailed description

Deep brain stimulation (DBS) stands as an established and robust treatment for various motor symptoms in patients with Parkinson's disease (PWP). While it has shown promise in ameliorating non-motor symptoms, the mechanisms underlying these improvements remain poorly understood. A significant forthcoming shift in the DBS landscape is the transition towards closed-loop or "adaptive DBS" (aDBS). This approach relies on expanding knowledge of basal ganglia electrophysiology and its correlation with motor symptoms. Augmented beta frequency oscillations (13-35 Hz) in local field potentials (LFP) from the basal ganglia is correlated with severity of the motor systems bradykinesia/rigidity and serve as an electrophysiological biomarker for clinical state. Essentially, aDBS aims to modulate stimulation in response to neural state, offering more precise symptom control.

Sleep disturbances are a prevalent symptom in PWP, affecting a vast majority of patients, and serve as a significant non-motor contributor to quality of life. While DBS has demonstrated benefits in enhancing sleep efficiency and architecture, the mechanisms by which this might occur, as well as the optimal stimulation parameters for treating sleep dysfunctions are unknown. Sleep is associated with a dramatic change in subcortical neural activity compared to the wake state, with decreased beta activity, which could serve as a neurophysiological biomarker for the sleep state. Since beta frequencies are a common target for adaptive DBS studies in PD, addressing sleep-induced reductions in beta activity will be crucial for future algorithm development. Incorrectly interpreting sleep as the "medication-on" state may result in an adaptive algorithm providing the patient with non-optimal stimulation amplitudes that may adversely affect sleep.

There is an urgent need to identify the dose-response curve regarding how stimulation affects sleep quality and neurophysiology. Our primary objective is to address this knowledge gap by obtaining a comprehensive understanding of the subcortical neural signatures of sleep, and their correlation with sleep outcomes under different stimulation currents. This will ultimately enable us to establish the control policy for adaptive control of stimulation amplitude (current). Our central hypothesis is that different stimulation currents will elicit distinct effects on sleep subcortical neural signatures and sleep quality.

Interventions

  • Other Nighttime Deep Brain Stimulation with Varying Amplitude Settings
    Participants will undergo three different nighttime-only Deep Brain Stimulation (DBS) settings in a randomized crossover design: 0% amplitude (stimulation off), 50% amplitude of their optimal clinical DBS settings, and full clinical DBS settings (100%). Each setting is applied for two weeks during sleep, over a total six-week home monitoring period. The intervention is designed to assess how varying levels of subthalamic nucleus DBS influence sleep quality and neural oscillatory activity. Only n

Primary outcome measures

  • To demonstrate differences in sleep efficiency (SE) among different stimulation settings. [Time frame: At the end of each 2-week stimulation period (over 6 weeks total)]
Secondary outcome measures (7)
  • Average Nightly Beta Band Power [Time frame: At the end of each 2-week stimulation period (over 6 weeks total)]
  • Correlation Between Sleep Efficiency and Beta Band Power [Time frame: Over each night during the 6-week study period]
  • Correlation of Wake After Sleep Onset (WASO) with Beta Band Power [Time frame: Across 6-week study period and at the end of each 2-week stimulation phase]
  • Coherence Across Deep Brain Stimulation Amplitude Settings [Time frame: At the end of each 2-week stimulation period (over 6 weeks total)]
  • Correlation of sleep fragmentation index with Beta Band Power [Time frame: Across 6-week study period and at the end of each 2-week stimulation phase]
  • Correlation of Pittsburgh Sleep Quality Index (PSQI) with Beta Band Power [Time frame: Across 6-week study period and at the end of each 2-week stimulation phase]
  • Correlation of and Epworth Sleepiness Scale (ESS) with Beta Band Power [Time frame: Across 6-week study period and at the end of each 2-week stimulation phase]

Eligibility criteria

Inclusion criteria

  • Male or female > 18 years of age
  • Diagnosed with idiopathic Parkinson Disease
  • Have bilateral implantation of Medtronic's PerceptTM PC (Medtronic Neurological Division, Minneapolis, MN, USA) Deep Brain Stimulation (DBS) system targeting the subthalamic nucleus (STN) and have had their stimulation settings optimized for a minimum of three months
  • Report a response score of one or greater on question 1.7 of the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part I;
  • Demonstrate ability to ambulate independently;
  • Be capable of providing informed consent;
  • If taking sleep-supporting medications, dosing must be stable for at least 30 days

Exclusion criteria

  • Presence of neurological diseases other than Parkinson Disease, such as stroke or multiple sclerosis
  • Active sleep disorders, including narcolepsy, moderate to severe (Apnea-Hypopnea Index>=15) untreated sleep apnea, uncontrolled restless legs syndrome
  • Cognitive impairment meeting the criteria for dementia as per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV), based on formal neuropsychological evaluation
  • Ongoing alcohol or substance abuse; Working night shifts or irregular work hours

The main concern for vulnerable subjects will be for the possibility of reduced decision-making capacity. For this we intend to exclude individuals who have a diagnosis of dementia.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Supportive care

Study locations

United States · 1 center
  • Cleveland Clinic — Cleveland

Identifiers

NCT: NCT07110376 · 25-323 DREAMS-PD

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗